Latest News and Press Releases

HORSHOLM, Denmark, April 27, 2006 (PRIMEZONE) -- The General Meeting approved the report of the Board of Directors and the Financial Statements. The Board of Directors' motion that the loss for the...

HOERSHOLM, Denmark, Feb. 1, 2006 (PRIMEZONE) -- Pharmexa has filed an application to obtain approval to initiate the phase III trial with GV1001 in Ireland. Further applications will be filed in a...

HORSHOLM, Denmark, Nov. 24, 2005 (PRIMEZONE) -- Pharmexa Summary: -- Pharmexa A/S ("Pharmexa") and IDM Pharma, Inc. ("IDM") have entered into an agreement whereby Pharmexa will acquire...

HORSHOLM, Denmark, Aug. 24, 2005 (PRIMEZONE) -- Summary: The Pharmexa Group generated revenue of DKK 1,756 thousand in the first six months of 2005 and realised a net loss of DKK 59,065 thousand....

HORSHOLM, Denmark, Aug. 16, 2005 (PRIMEZONE) -- Summary: Pharmexa has seen promising preliminary results from a phase II trial of the company's breast cancer vaccine and received approval to start an...

HORSHOLM, Denmark, Jan. 23, 2004 (PRIMEZONE) -- H. Lundbeck and Pharmexa have entered into an option agreement, whereby H. Lundbeck will invest DKK 10 million on the same terms as other shareholders...

HORSHOLM, Denmark, Jan. 19, 2004 (PRIMEZONE) -- Pharmexa has completed the first clinical trial with HER-2 Protein AutoVac(TM) in 10 breast cancer patients in the US. The data show that the vaccine...

HORSHOLM, Denmark, Nov. 20, 2003 (PRIMEZONE) -- Pharmexa -- Summary: The preliminary data from a phase I trial with the HER-2 Protein AutoVac(TM) vaccine in 10 breast cancer patients in the US...

HORSHOLM, Denmark, Nov. 17, 2003 (PRIMEZONE) -- Summary: A new analysis shows that a TNF-alpha vaccine based on Pharmexa's (Other OTC:PMXAY) AutoVac(TM) technology induced antibodies in approximately...

HORSHOLM, Denmark, Sept. 10, 2003 (PRIMEZONE) -- Summary: Recruitment of patients to the US phase I breast cancer trial with Pharmexa's (Other OTC:PMXAY) HER-2 AutoVac(TM) Protein vaccine has now...